The Future of Wellness in an AI World
AI Is Redefining Consumer Expectations, Even in the Nutraceutical Sector. Brand Strategies Should Adjust, Too. FORT LAUDERDALE, Fla., June 2,...
Brain
Sapience Therapeutics Provides Data Update from Phase 2 Trial of Lucicebtide in Patients with Glioblastoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
-Clinical benefit and favorable safety profile as monotherapy and in combination with SOC- -Biomarker data supports MOA: decreased GBM mesenchymal...
Hyperfine Announces FDA Clearance of a New Next-Generation Swoop® System Powered by Optive AI™ Software, Delivering a Transformative Leap in Image Quality
This major Swoop® system scanner redesign and Optive AI™ software elevate the AI-powered portable MRI experience for clinicians and their...
Hyperfine Announces FDA Clearance of a New Next-Generation Swoop® System Powered by Optive AI™ Software, Delivering a Transformative Leap in Image Quality
This major Swoop® system scanner redesign and Optive AI™ software elevate the AI-powered portable MRI experience for clinicians and their...
PreveCeutical Welcomes Dr. Deepak Sampath, PhD. as Corporate Advisor
Vancouver, British Columbia--(Newsfile Corp. - June 2, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"),...
Silo Wellness to Relist as Born Defense, a National Security Investment Issuer Focused on Ending Forever Wars and Upholding the Just War Doctrine
Eugene, Oregon and Toronto, Ontario--(Newsfile Corp. - June 2, 2025) - Silo Wellness Inc. (CSE: SILO) ("Silo," or the "Company")...
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-‘749 (olanzapine) to Date
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED)...
Updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommend Use of FES PET Imaging for Lobular Breast Cancer
NCCN Guidelines® recommend FES PET for systemic staging in certain patients with invasive lobular cancer (ILC), which could facilitate greater...
Shareholder Update
May 30, 2025 Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage...
Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis
Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two...
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference
BRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform...
UP Fintech: Profit Hits Record High; Client Assets Reached US$45.9 Billion
NEW YORK, May 30, 2025 /PRNewswire/ -- UP Fintech Holding Limited (NASDAQ: TIGR) ("UP Fintech" or the "Company"), announced its unaudited...
The Brain Prize: HM The King of Denmark presents prestigious prize to US and German scientists for seminal discoveries in brain cancer
Two pioneering scientists received The Brain Prize 2025 for their discoveries that open an entirely new way of thinking about...
NeuLogiq® Platform Confirms Electrophysiological Marker of Target Engagement in Patients with Major Depressive Disorder
Data presented by Delix Therapeutics at the 2025 American Society of Clinical Psychopharmacology (ASCP) Conference confirms the NeuLogiq® Platform is...
Brainomix Driving Treatment Decisions in Stroke: New Studies Presented at Leading European Stroke Conference
New evidence from the largest prospective evaluation of stroke AI imaging further validates Brainomix 360 Stroke impact on mechanical thrombectomy,...
BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic
IND submission planned for mid-2025 with Phase 1 SAD data anticipated by year end BGE-102 induced weight loss in preclinical...
Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders
Transaction is anticipated to be completed in third quarter 2025 Planned Cortigent Nasdaq listing intended to drive value for Vivani...
LandingAI Launches Agentic Document Extraction for Unlocking Insights from Complex Documents
Transforming Enterprises Complex Document Workflows and Understanding with Agentic Vision Technologies PALO ALTO, Calif., May 28, 2025 /PRNewswire/ -- LandingAI,...
Immunotherapeutic Targets for Recurrent Medulloblastoma Receives $85K Grant from Brain Cancer Canada
TORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- Brain Cancer Canada is proud to award $85,000 to a groundbreaking research project...
Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference
SEATTLE and VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage specialty...